Cognition Therapeutics(US:CGTX) Globenewswireยท2025-05-07 11:30Core Insights - Cognition Therapeutics is advancing its Alzheimer's disease and dementia with Lewy bodies (DLB) programs, requesting an end-of-Phase 2 meeting with the FDA to discuss the SHINE study results and plans for a registrational study [2][9] - The company reported a net loss of $8.5 million for Q1 2025, an improvement from a net loss of $9.2 million in Q1 2024, with a loss per share of $(0.14) compared to $(0.27) in the prior year [7][13] - Cash and cash equivalents as of March 31, 2025, were approximately $16.4 million, with total obligated grant funds remaining at $47.0 million, indicating sufficient cash to fund operations into Q4 2025 [4][12] Business and Corporate Highlights - The Phase 2 results in DLB were accepted for oral presentation at the Alzheimer's Association International Congress (AAIC) scheduled for July 27-31, 2025 [9] - Two posters will be presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting, highlighting zervimesine's role in retinal cell health [9] - The company is in the process of securing a commercial investigational new drug (IND) application for zervimesine in DLB to facilitate separate EOP2 meetings for each indication [2] Financial Results - Research and development expenses for Q1 2025 were $10.8 million, slightly up from $10.6 million in Q1 2024, primarily due to increased Phase 2 trial activities [5] - General and administrative expenses decreased to $3.0 million in Q1 2025 from $3.5 million in Q1 2024, attributed to lower stock compensation [6] - Total operating expenses for Q1 2025 were $13.775 million, down from $14.102 million in the same period of 2024 [12]